JDRF Blog
Dexcom G7 Continuous Glucose Monitor Cleared by the FDA
Dexcom G7® Continuous Glucose Monitor system was cleared by the FDA, giving people with diabetes more options for managing their blood-sugar levels.
Read More About Dexcom G7 Continuous Glucose Monitor Cleared by the FDA
Verapamil Slows Type 1 Diabetes Progression in Newly Diagnosed Children and Teens
The CLVer study found that newly diagnosed individuals on verapamil were making more insulin one year after diagnosis than those on placebo.
Read More About Verapamil Slows Type 1 Diabetes Progression in Newly Diagnosed Children and Teens
FDA Approves Tzield™—A Watershed Moment for the T1D Community
JDRF celebrates the FDA approval of Tzield, the first disease-modifying therapy to delay clinical T1D in people at risk of developing the disease.
Read More About FDA Approves Tzield™—A Watershed Moment for the T1D Community
TypeOneNation Summits: All New for 2023
JDRF's 2023 TypeOneNation Summits have an exciting new approach to educate and inspire the type 1 diabetes (T1D) community.
Read More About TypeOneNation Summits: All New for 2023Recent Articles
Sign up for our monthly Research Newsletter, The Pipeline, to stay up to date on the latest and greatest in T1D science.
By clicking Sign Up, I agree to the JDRF Privacy Policy. I also agree to receive emails from JDRF and I understand that I may opt out of JDRF subscriptions at any time.